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Abstract
Background: By persisting in infected cells for a long period of time, proviral HIV-1 DNA can
represent an alternative viral marker to RNA viral load during the follow-up of HIV-1 infected
individuals. In the present study sequential blood samples of 10 patients under antiretroviral
treatment from 1997 with two NRTIs, who refused to continue any antiviral regimen, were
analyzed for 16 – 24 weeks to study the possible relationship between DNA and RNA viral load.
Methods: The amount of proviral DNA was quantified by SYBR green real-time PCR in peripheral
blood mononuclear cells from a selected group of ten patients with different levels of plasmatic
viremia (RNA viral load).
Results: Variable levels of proviral DNA were found without any significant correlation between
proviral load and plasma HIV-1 RNA levels. Results obtained showed an increase or a rebound in
viral DNA in most patients, suggesting that the absence of therapy reflects an increase and/or a
persistence of cells containing viral DNA.
Conclusion: Even though plasma HIV RNA levels remain the basic parameter to monitor the
intensity of viral replication, the results obtained seem to indicate that DNA levels could represent
an adjunct prognostic marker in monitoring HIV-1 infected subjects.
Background
Many papers have clearly demonstrated that HIV-1 RNA
plasma viral load quantitative determination is a pivotal
parameter to monitor viral replication and the effective-
ness of HAART therapy [1-5]. In addition, a growing
number of observations showed that measurement of
HIV-1 DNA proviral load could provide crucial informa-
tion on the reservoir and dynamics of HIV-1 infection
[5,6] since the persistence of HIV-DNA in peripheral
blood mononuclear cells (PBMC) and lymph nodes is a
major drawback to eradication of infection [7,8]. Quanti-
tative analysis of proviral DNA in HAART-treated patients
showed opposite results: on one hand, the decline in DNA
load seemed to indicate the long term impact and effec-
tiveness of retroviral treatment [9-12], on the other DNA
levels remained stable over several years in PI ART naïve
patients [2,13].
Recent studies also indicate that viral replication persists
even in individuals with prolonged suppression of plasma
HIV-1 RNA levels to fewer than 50 copies/ml [5,8,14-16],
confirming that "undetectable viremia" cannot be
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considered evidence of complete viral replication suppres-
sion. The findings of a slow and/or incomplete decay
imply that current HAART regimens do not completely
suppress viral replication. However the decreasing mor-
bidity and mortality in HAART-treated HIV-1 seropositive
patients and the following restoration, preservation of
immunologic function and improvement in quality of life
demand the ongoing use of these drugs. The new thera-
peutic challenge is to find new immunological or pharma-
cological approaches aimed at purging HIV-1 DNA
proviral reservoirs [19]. Several recent studies have
addressed structured treatment interruption (STI), as con-
ceivable strategy to stimulate and enhance the immune
system HIV-1 specific response to tackle viral replication
in the absence of chemotherapy [17-19] even though sev-
eral reports showed that only 10–20% of chronically
infected patients achieved a short-term suppression of
viral replication [20-22].
Since a growing number of studies involving quantifica-
tion of cellular HIV-1 DNA acknowledge the importance
of accurate quantification of proviral DNA in peripheral
blood cells for monitoring diseases progression, we
selected a small but peculiar group of patients, who
decided to interrupt antiretroviral therapy, irrespective of
current guidelines [23] and despite virologic failure. In
particular, sequential blood samples of 10 patients under
antiretroviral treatment from 1997 with two NRTIs, who
refused to continue any antiviral regimen, were analyzed
for 16 – 24 weeks to study the possible relationship
between DNA and RNA viral load.
Methods
Patients
Ten HIV-1 infected adults under antiretroviral treatment
since 1997 with two NRTIs (stavudine [D4T] and lamivu-
dine [3TC] or zidovudine [AZT] and lamivudine [3TC] or
zidovudine [AZT] and zalcitabina [DDC] or zidovudine
[AZT] and didanosine [DDI]) were selected for this study.
All these patients refused to continue any antiviral regi-
men despite an assessed virologic failure (HIV-1 RNA viral
load > 50 copies/ml) and were followed-up monthly for a
variable period ranging from 16 to 24 weeks up to the
moment in which they agreed to begin a new therapeutic
protocol. Sequential blood samples were obtained at
baseline (time 0: voluntary therapy interruption) and
every four weeks (time 1-time 7) and analyzed for viral
load (RNA and DNA), and CD4 levels. The baseline char-
acteristics of the patients included in the study are shown
in Table 1. All the subjects were enrolled after informed
consent according the Helsinki declaration of 1975.
HIV-1 RNA quantification
All the whole blood samples were centrifuged at 2500
rpm for 20 min and plasma was stored at -80°C until use.
Plasma was analyzed for HIV-1 RNA viral using the Quan-
tiplex HIV-RNA-3.0 assay (Chiron Corporation, Emery-
ville, CA, USA), according to the manufacturer's
instructions. The amount of HIV RNA levels was expressed
as copy number per ml of plasma and the lowest detection
limit of the assay was 50 copies/ml.
DNA extraction and purification of PBMCs for HIV-1 DNA 
quantification
Peripheral blood mononuclear cells (PBMC) were iso-
lated from whole blood by Ficoll-Paque gradient separa-
tion (Amersham Pharmacia). Cell pellets, corresponding
to 5 × 106 PBMC were prepared and stored at -80°C. DNA
was extracted and purified from each PBMC pellet by
DNAeasy tissue kit (Qiagen) following the manufacturers'
instructions. The pGEMBH10 HIV plasmid [8,14] was
purified by Midi plasmid extraction kit (Qiagen, Hilden,
Germany) following the manufacturers' instructions.
Plasmid and cellular DNA concentration and purity were
determined by spectrophotometric analysis at 260/280
nm.
Determination of HIV-1 proviral DNA by SYBR green real-
time PCR
SYBR green real-time PCR assay was performed, as previ-
ously described [8,14] in 20 µl PCR mixture volume con-
sisting in 2× Quantitect SYBR Green PCR Master Mix
(Qiagen) containing HotStarTaq DNA polymerase, 200
nM of each oligonucleotide primer (SK431, SK462) [24]
and 600 ng of DNA extracted from clinical samples
(approximately the DNA content of 200.000 cells) or sca-
lar dilution of pGEMBH10 HIV plasmid (from 105 to 10
copies). Initial activation of HotStar Taq DNA Polymerase
at 95°C for 15 min; 45 cycles in four steps: 94°C for 10 s,
60°C for 30 s, 72°C for 30 s, 78°C for 3 s. At the end of
amplification cycles, melting temperature analysis was
carried out by a slow increase in temperature (0.1°C/s) up
to 94°C. Amplification, data acquisition and analysis
were carried out by a LightCycler instrument (Roche,
Mannheim, Germany) using LightCycler 5.3.2 software
(Roche). This software, coupled with the LightCycler
Table 1: Baseline characteristics of HIV infected patients 
enrolled in the study at time of therapy suspension.
Characteristic
Gender 7 males, 3 females
Heterosexual 8
IVDUs 2
Age (mean years ± SD) 36.27 ± 8.32
CD4 count cells × 106 per l (median) 548.45 ± 63 cells/mmc.
Plasma HIV-1 RNA copies/ml (median) 3.7 × 103BMC Infectious Diseases 2005, 5:69 http://www.biomedcentral.com/1471-2334/5/69
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instrument, determines the threshold cycle (Ct) represent-
ing the number of cycles in which the fluorescence inten-
sity is significantly above the background fluorescence. Ct
is directly proportional to log10 of the copy number of the
input templates with respect to a standard curve generated
in parallel. SYBR green molecules bind all double
stranded DNA molecules emitting a fluorescent signal, on
binding, proportional to the amplicon synthesis during
the PCR reaction. This property elicited an accurate analy-
sis of the melting temperature curve of the amplified frag-
Table 2: Longitudinal values of HIV RNA and DNA viral load, CD4 levels in patients on long term treatment with two NRTIs from 
therapy suspension (time 0) onwards.
RNA Viral Load 
(copies/ml)
DNA Viral Load 
(copies/
106PMBCs)
CD4 cell count 
(x106cells/L)
RNA Viral Load 
(copies/ml)
DNA Viral Load 
(copies/
106PMBCs)
CD4 cell count 
(x106cells/L)
Pt 1 Pt6
Time0 6300 335 Time0 2940 625
Time1 20800 1600 324 Time1 2500 1100 625
Time2 30000 2200 324 Time2 16000 1400 529
Time3 58000 1800 340 Time3 7800 630 625
Time4 100000 2000 300 Time4 25000 620 552
Time5 120000 3800 220 Time5 24000 730 750
Pt2 Time6 17000 890 483
Time0 11000 345 Pt 7
Time1 22000 1200 345 Time0 1600 462
Time2 70000 1900 365 Time1 6800 920 450
Time3 100000 1500 256 Time2 1700 750 456
Time4 150000 1000 304 Time3 4400 910 384
Time5 148000 770 240 Time4 4000 690 380
Time6 170000 990 238 Time5 2700 400 399
Pt3 Time6 2800 300 342
Time0 3600 551 Pt8
Time1 43000 2300 448 Time0 3970 616
Time2 58100 820 266 Time1 4000 1000 616
Time3 49000 580 560 Time2 85000 660 532
Time4 58000 990 360 Time3 100000 490 361
Pt4 Time4 84000 230 420
Time0 1220 572 Time5 74000 330 456
Time1 1400 1300 570 Time6 100000 550 460
Time2 24000 1890 522 Pt9
Time3 46000 960 572 Time0 10500 680
Time4 27000 500 576 Time1 14000 1500 624
Time5 32000 700 432 Time2 16000 1000 480
Time6 31000 550 348 Time3 39000 450 588
Pt5 Time4 33000 1100 520
Time0 4900 494 Time5 145000 3100 390
Time1 93000 1500 528 Pt10
Time2 100000 1050 483 Time0 1130 578
Time3 150000 830 460 Time1 69000 612 420
Time4 250000 1000 404 Time2 66000 1200 320
Time3 100000 1600 350
Time4 210000 2800 267BMC Infectious Diseases 2005, 5:69 http://www.biomedcentral.com/1471-2334/5/69
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ments generated by real-time PCR to determine the
detection and quantitation of specific products. Thus the
single analysis of fluorescence was performed at 75°C by
LightCycler 5.3.2 software in each cycle to rule out any
non-specific interference (i.e. dimer primer). All samples
from patients were run in duplicate and were also ana-
lyzed by SYBR Green real-time PCR for globin gene in a
parallel run to check the equal amount in all samples
determined by spectrophotometric data as described.
Statistical analysis
Statistical analysis was carried out using Student's t-test or
Mann-Whitney test. Correlation was determined by
Spearman's rank correlation.
Results
Longitudinal analysis of RNA plasma viral load detection 
by b-DNA assay
As expected, therapy interruption determined a significant
increase in RNA viral load in all HIV-1 seropositive
patients enrolled in the study. In particular, all patients'
plasma showed a significant (Mann-Whitney test p =
0.036) increase in viral load already one month after ther-
apy interruption (time 1) showing a median value of 1.7
× 104 (4.2 log10) in comparison to 3.7 × 103 copies/ml
(3.5 log10) observed at median baseline value (time 0).
Moreover, plasma viral load reached higher levels
[median value of 1,1 × 105 HIV-1RNA copies/ml (5 log10)]
at the end of observation period (p = 0.014) (Table 2).
Hence, we assessed an increase in viral replication ranging
from 0.5 log10 to more than 1 log10 at the end of observa-
tion period (p = 0.00).
Longitudinal analysis of PBMC DNA proviral load 
detection by quantitative real time PCR assay
In parallel experiments, we quantified proviral DNA load
in PBMC isolated from patients' whole blood sequential
samples at fixed times after therapy suspension. The
median number of samples available for each patient was
five [1 month after the therapy suspension (time 1) and
then each month up to the end of observation period],
ranging from two to seven. The median follow-up was 5.5
(4–7) months.
The majority of patients showed a fluctuating trend in
DNA viral load. Three patients (N°1, N°9 and 10)
showed an increase in DNA viral load detectable from the
first through to the last available sample. Even though
DNA amount reached a significantly (considered as a var-
iation of 0.5 – 1 log10) higher value only in samples from
patients N°1 and N°10 (from 3.2 log10 to 3.7 log10 and
from 2.7 log10 to 3.4 log10 respectively), sequential PBMC
samples obtained from patient N°9 exhibited a clear ten-
dency to increase (and from 3.1 log10 to 3.5 log10 copy of
HIV-1 DNA per 106 PBMCs respectively) redoubling the
DNA content. Moreover, most of the other samples
obtained from patients N°2, N°3, N°4, N°5 and N°6
showed a swinging course. After an apparent decline in
proviral DNA content during the follow-up, in the latest
samples a moderate increase in proviral DNA load was
observed in PBMC from all patients. In contrast, a
decrease of HIV-1 proviral DNA content was noticed from
a baseline value of 1.3 × 103 copies per ml (3.1 log10) to
5.5 × 102 HIV-1 DNA copies per ml (2.7 log10) and from
9.2 × 102 (2.9 log10) to 3.0 × 102 (2.4 log10) in patients
N°4 and 7 only.
As expected, a statistical analysis of PBMCs HIV proviral
DNA content and plasma RNA viral load of all 10 patients
failed to disclose any significant correlation between HIV-
1 proviral DNA load and HIV-1 RNA viral load (Mann-
Wittney test) confirming our previous data [14].
CD4 cell count determination
All the patients enrolled in the study showed a CD4 reduc-
tion during the follow-up. All patients, except two
(Patients N°1 and N°2), interrupted therapy with a level
of CD4 cells >400 cells/mmc and, as expected, showed a
sharp [(N°1 and N°3 (34% reduction), N°2 (31% reduc-
tion), N°4 (39%), N°9 (42%), N°10 (53%)] decrease or
a moderate decline [N°5 (18% reduction), N°6 (22%
reduction) N°7 and 8 (25% reduction)] at the end of our
observation period. No correlation was found (r = 0.5, p
> 0.005) between the course of DNA viral load and CD4
levels, but high RNA levels were significantly associated
with lower CD4 counts, demonstrating a significant
inverse correlation between CD4+ cell counts and HIV-1
RNA levels (p = 0.001).
Discussion
During recent years, planned therapy interruption has
been entertained in specific clinical situations even
though the potential role of this choice with respect to the
balance between risk of disease progression and potential
benefits remains to be elucidated. Our study focused on a
peculiar group of patients who voluntary opted to sus-
pend antiretroviral therapy for a variable period of time,
ranging from five to seven months, despite of virologic
failure. Our follow-up ceased when patients agreed to a
new therapeutic protocol.
Our study aimed to evaluate the virologic evolution of
these subjects focusing on DNA proviral load course, since
accurate quantification of HIV-1 DNA in peripheral blood
cells is an important parameter for monitoring disease
progression and predicting the clinical outcome of infec-
tion [3,27-29]. Several studies, mostly addressed to
patients under different therapy protocols, have shown
that the evaluation of DNA content may have important
implications for understanding the virological response toBMC Infectious Diseases 2005, 5:69 http://www.biomedcentral.com/1471-2334/5/69
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combination therapy [25,26]. Even thought the plasma
HIV-1 RNA load is widely considered a direct indicator of
viral replication in infected individuals, the formation,
stability and turnover of potentially infectious virus in the
HIV-1 DNA proviral pool has important indication for the
understanding of HIV pathogenesis [5,6,11]. Moreover,
Vitone et al. [8] recently demonstrated that the decrease in
HIV-1 DNA proviral load is inversely correlated to CD4
level in HIV-1 seropositive patients with a persistently
undetectable viremia (HIV-1 RNA viral load).
Current data on course of DNA viral load during infection
are inconclusive [1-9], but most studies suggest that HIV-
1 DNA proviral quantification is useful to monitor the
decay of the HIV reservoir towards disease remission, dis-
tinguishing "responder" from "non responder" patients
[3,28].
Our results, obtained from patients, therapy-free during
the virolgical follow-up, showed a viral rebound, one
month after therapy suspension, assessed by plasma RNA
values in all patients. The analysis of HIV-1 DNA proviral
content displayed a clear increase from the baseline value
in three patients, confirming that an active viral replica-
tion results in elevated viremia (HIV-1 RNA load) and in
an increased number of cells containing viral DNA
[27,28]. Also, patients who showed an apparent decrease
in DNA copy number during the first step of our follow-
up, came to present a rebound of DNA in PBMCs at the
end of observation period. These observations might sug-
gest that previous therapy controlled the amount of viral
DNA only for a limited period of time and a likely viral
rebound, as assessed by an increase in DNA amount, was
observed only some months later.
Finally, in contrast with other patients, two subjects
showed a clear HIV-1 DNA proviral decrease over time, in
the absence of therapy and a steady HIV-1 RNA viral load
detectable in plasma samples. In both cases a HIV-1 DNA
proviral decline due to a long lasting effect of therapy
could be ruled out, since both patients showed high levels
of viral replication by increasing value of HIV-1 RNA viral
load over time. In an attempt to explain the course of HIV-
1 DNA proviral in these subjects, we had to take into con-
sideration that our assay, a SYBR green based real time
PCR measures both integrated and unintegrated HIV-1
DNA form on PBMCs. There is evidence that only a frac-
tion of integrated and unintegrated HIV-1 DNA is replica-
tion competent [25]. Hence, it is possible that most of the
HIV-1 DNA, displayed in our two patients, might be
mainly represented by integrated DNA fully capable of
initiating HIV replication. Our data are confined to results
related to proviral DNA in PBMCs, even if we must con-
sider that viral load is also sustained by lymph node
trapped CD4 T cells and other non circulating elements
[6] that preserve replication competent virus for long peri-
ods. In the absence of therapy, a large number of HIV-1
DNA proviral copies might replicate, as assessed by the
HIV-1 RNA viral load increase, leading to a relative decline
of cellular DNA. In addition, we cannot exclude a further
increase in DNA content in a longer follow-up.
Despite contrasting reports on the meaning of DNA pro-
viral content in HIV-1 seropositive patients [2,5,9-12], our
data obtained on closely controlled patients, emphasize
the interest of studying DNA proviral content in HIV-1
infected patients. Even though it is impossible to define a
proviral DNA threshold for use in clinical practice, several
data showed that patients with high proviral DNA levels
are more likely to experience virological failure than those
with lower proviral DNA loads [11]. Moreover the provi-
ral load probably reflects individual parameters because
host genetic factors and response to treatment probably
are involved in the constituting the pool of infected cells
[30,31]. Although RNA viral load provides important
information on viral replication, HIV-1 DNA proviral
load can be considered an additional marker to provide
crucial information, not only during the follow-up of
patients under therapy but also for individuals included
in structured therapy interruptions protocols. Data
obtained from our patients, who were not part of
antiretroviral protocols [23], yield important information
on the persisting timing of DNA in PBMCs.
Conclusion
Only careful evaluation of virological and immunological
markers is necessary to fully characterize the course of
HIV-1 infection and to provide a more complete labora-
tory-based assessment of disease progression. However,
the availability of a new standardized assay such as DNA
proviral load will be important to assess the true extent of
virological suppression in patients with non-quantifiable
plasma viral loads and to verify the efficacy of new
immune-based therapies aimed at purging HIV-1 DNA
reservoirs. Although the biological meaning of DNA pro-
viral load in PBMCs is not yet clear, several studies
[2,3,6,10] suggest that HIV-1 cellular DNA load may be an
indicator of spread of infection whereas the plasma RNA
load is indicates active infection [2]. However the qualita-
tive and quantitative evaluation of both plasma HIV RNA
genome and HIV-1 proviral DNA might prove crucial to
understanding the course of HIV-1 infection.
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